Figure 13 is a forest plot depicting our meta-analysis on the percent of patients achieving “response” as measured by the Hamilton depression scale (HAM-D), for depression augmentation studies. Two placebo controlled trials of 5 to 20 mg/ day olanzapine augmentation by the same authors had statistically insignificant results. Three placebo controlled trials of augmentation with quetiapine at various doses showed a statistically significant pooled estimate of the relative risk of response of 2.30. Three placebo controlled augmentation trials of risperidone at various doses showed a statistically significant pooled estimate of the relative risk of response of 1.50.

Figure 13Depression—HAM-D % responded, augmentation

From: Results

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.